Claims for Patent: 5,595,997

Summary for Patent: 5,595,997

Title:	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
Abstract:	Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Inventor(s):	Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA)
Assignee:	Sepracor Inc. (Marlborough, MA)
Application Number:	08/366,651
Patent Claims:	1. A method of treating allergic rhinitis in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of descarboethoxyloratadine or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion. 3. The method of claim 1 wherein said human has a higher than normal propensity for or incidence of cancer. 4. The method of claim 1, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided. 5. The method of claim 1 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day. 6. The method of claim 5 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day. 7. The method of claim 1 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.